Secukinumab 150 mg in 1 mL Prefilled Syringe
RxNorm 1599792
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1599792 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: secukinumab 150 mg in 1 mL Prefilled Syringe.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
1 mL secukinumab 150 mg/ML Prefilled Syringe
(Atom ID: 6824731)
PSNPrescribable
Prescribable Name (PSN):
Secukinumab 150 mg in 1 mL Prefilled Syringe
(Atom ID: 7244652)
SYPrescribable
Synonym (SY):
Secukinumab 150 mg/ML 1ML Prefilled Syringe
(Atom ID: 6827252)
Patient Education
Secukinumab Injection
Secukinumab injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. It is also used in adults to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin). Secukinumab injection is used in adults to treat ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas, causing pain, swelling, and joint damage). It is also used in adults to treat active non-radiographic axial spondyloarthritis (a condition in which the body attacks the joints of the spine and other areas, causing pain and signs of swelling, but without changes seen on x-ray). Secukinumab injection is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.
[Learn More]
* Please review the disclaimer below.